Long-term growth and bone development in children of HBV-infected mothers with and without fetal exposure to tenofovir disoproxil fumarate

Wen, Wan–Hsin; Chen, Huey‐Ling; Shih, Tiffany Ting-Fang; Wu, Jiafeng; Ni, Yen‐Hsuan; Lee, Chien‐Nan; Zhao, Lulu; Lai, Ming‐Wei; Mu, Shu‐Chi; Tung, Yi‐Ching; Hsu, Hong‐Yuan; Chang, Mei–Hwei; Shyu, Ming‐Kwang; Hwa, Hsiao‐Lin; Su, YC; Shih, Jin-Yuan; Chao, Kang; Chiu, Yu-En; Chang, Kai Chi; Liu, C.J.; Su, Tung‐Hung; Chen, D.S.; Chen, S.M.; Lin, Chun‐Chi; Lin, Pei; Yang, W.R.; Hu, Jen‐Jan; Yang, Cai-xia; Chang, Yu-Ting; Chen, K.H.; Lin, Ho-Hsiung; Lin, Yu‐Hui; Chen, H.J.; Pan, Heng‐Yu; Lau, Beng-Huat; Lee, C.L.; Cheng, Po‐Jen; Chang, Yuh‐Lih; Chiueh, Ho-Yen; Wang, T.H.; Hsu, Jane Yung-jen; Lo, Lan; Hsieh, Chin-Wen; Cheng, Shao Wen; Tsai, Ming‐Song; Lin, Liansheng; She, Bin; Peng, Feng; Lin, You‐Yu; Chen, C.P.; Huang, Jiancheng; Yeung, Chun‐Yan

doi:10.1016/j.jhep.2020.01.021

Cited by 27 publications

(21 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The concern of bone and renal complications in infants born to mothers who used anti‐viral therapy during pregnancy is low. While there is a lack of evidence from the US, a recent study conducted by the Taiwan Study Group for the Prevention of Mother‐to‐Infant Transmission of HBV (the PreMIT study) confirmed prior safety reports with their observation that the receipt of TDF in HBsAg‐positive mothers during their pregnancy did not adversely affect their children's bone growth, long‐term growth and renal function up to 6‐7 years after delivery 30 …”

Section: Gaps In Hbv Vaccination and Preventionmentioning

confidence: 66%

Review article: current gaps and opportunities in HBV prevention, testing and linkage to care in the United States—a call for action

Yeo

Nguyen

2020

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SummaryBackgroundThe World Health Organization (WHO) has set an elimination goal for hepatitis B virus (HBV) by 2030, so a comprehensive review of current HBV testing and care gaps are needed to help formulate solutions and opportunities for action.AimsTo summarise current gaps and barriers, and to propose solutions for HBV prevention, testing and linkage to care in the United StatesMethodsRelevant guidelines and studies were reviewed including a systematic review of HCC surveillance adherence.ResultsA total of 64.5 million (95% CI, 61.3‐67.5) high‐risk US adults had no evidence of HBV immunity. Only 18.6% (95% CI, 13.5‐29.9) of privately insured patients with HBV infection have been diagnosed. Among those with known HBV infection, linkage to care rate (33.3%‐57%) was poor and the adherence to guidelines regarding anti‐viral therapy (30.66% [95% CI, 30.28‐31.03]) and HCC surveillance (8%‐87%, from a systematic review) were poor with even more concerning data for care and treatment retention. The causes are complex and include lack of access to medical care, lack of physician knowledge, lack of patient health literacy and awareness, linguistic and cultural barriers and fear of stigma.ConclusionsA ‘scale‐up’ effort is needed to optimise the care continuum to achieve the WHO 2030 targets. As targeted screening policy has leftover 80% of patients undiagnosed, we advocate for universal screening which can help to remove barriers regarding stigma. More active and system level interventions are also needed to improve linkage to care for patients with HBV infection.

show abstract

Section: Gaps In Hbv Vaccination and Preventionmentioning

confidence: 66%

Review article: current gaps and opportunities in HBV prevention, testing and linkage to care in the United States—a call for action

Yeo

Nguyen

2020

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…A recent study by Wen et al showed that children with and without fetal exposure to TDF were similar in terms of bone development, long term growth and renal function up to 6-7 years after delivery [27].…”

Section: Infant Outcomes After Maternal Tdf Use During Pregnancymentioning

confidence: 99%

Tenofovir disoproxil fumarate for preventing mother-to-child transmission of hepatitis B: a literature review

Baciu¹,

Domuncu²,

Domuncu³

et al. 2021

Clin. Exp. Obstet. Gynecol.

View full text Add to dashboard Cite

Infection with the hepatitis B virus (HBV) is one of the leading global public health issues. Over 250 million people worldwide have chronic HBV infection, out of which roughly 65 million are women in their reproductive age. The most common route of passing the infection in areas of high endemicity is by mother-to-child transmission (MTCT). In children the infection may still occur despite adequate immunoprophylaxis, however, antiviral medication, such as Tenofovir disoproxil fumarate (TDF), may be helpful in reducing the risk of MTCT. A literature review was conducted concerning TDF’s role in preventing MTCT and its safety in pregnancy. Studies were identified by researching various databases up to 2020 for variations of the following sentence: “Tenofovir disoproxil fumarate and Lamivudine and Telbivudine and Entecavir and pregnancy and transmission and safety and HBV”. Prenatal and perinatal adequate management of maternal HBV infection is of utmost importance, with focus on prevention of MTCT as the key strategy to reduce the global HBV infection burden. This review discusses the most up-to-date evidence from a multidisciplinary perspective of using TDF to reduce MTCT of HBV infection as well as its safety profile for pregnant women.

show abstract

“…Although the efficacy and short-term safety of TDF during pregnancy are well established in this special population, 4-7 the long-term safety data are not sufficient since there exists only one relevant study published with a small sample size. 8 Similar to TDF, suppressing HBV DNA replication with TAF appears to be a potential option for the highly viraemic mother with chronic hepatitis B (CHB). From the investigators' perspective, previously published studies on the role of TDF for preventing HBV transmission have provided the roadmaps and research networks to further explore TAF during pregnancy.…”

Section: Authors' Replymentioning

confidence: 99%

“…The authors concluded that TDF for mothers with HBV DNA >200 000 IU/mL was highly effective at reducing the risk of HBV transmission without an increased risk of any infant or maternal safety outcomes. Although the efficacy and short‐term safety of TDF during pregnancy are well established in this special population, 4‐7 the long‐term safety data are not sufficient since there exists only one relevant study published with a small sample size 8 . Similar to TDF, suppressing HBV DNA replication with TAF appears to be a potential option for the highly viraemic mother with chronic hepatitis B (CHB).…”

mentioning

confidence: 99%

Editorial: tenofovir alafenamide fumarate—a new bullet to prevent mother‐to‐child transmission of hepatitis B virus. Authors' reply

Pan

Cao

Huang

2020

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Long-term growth and bone development in children of HBV-infected mothers with and without fetal exposure to tenofovir disoproxil fumarate

Cited by 27 publications

References 33 publications

Review article: current gaps and opportunities in HBV prevention, testing and linkage to care in the United States—a call for action

Review article: current gaps and opportunities in HBV prevention, testing and linkage to care in the United States—a call for action

Tenofovir disoproxil fumarate for preventing mother-to-child transmission of hepatitis B: a literature review

Editorial: tenofovir alafenamide fumarate—a new bullet to prevent mother‐to‐child transmission of hepatitis B virus. Authors' reply

Contact Info

Product

Resources

About